(-0.87%) 5 071.88 points
(-1.02%) 37 995 points
(-1.02%) 15 819 points
(-0.85%) $81.93
(-1.08%) $2.01
(-2.08%) $2 308.70
(-3.51%) $26.69
(-1.77%) $944.50
(0.42%) $0.936
(0.91%) $11.08
(0.47%) $0.800
(-0.01%) $93.29
3.07% HKD 3.36
Live Chart Being Loaded With Signals
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally...
Stats | |
---|---|
Tagesvolumen | 7.05M |
Durchschnittsvolumen | 501 174 |
Marktkapitalisierung | 13.41B |
EPS | HKD0.0135 ( 2023-09-30 ) |
Last Dividend | HKD0.112 ( 2023-05-24 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -5.69 |
ATR14 | HKD0.00800 (0.24%) |
Volumen Korrelation
Shenzhen Hepalink Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Shenzhen Hepalink Korrelation - Währung/Rohstoff
Shenzhen Hepalink Finanzdaten
Annual | 2023 |
Umsatz: | HKD5.45B |
Bruttogewinn: | HKD1.80B (33.06 %) |
EPS: | HKD-0.530 |
FY | 2023 |
Umsatz: | HKD5.45B |
Bruttogewinn: | HKD1.80B (33.06 %) |
EPS: | HKD-0.530 |
FY | 2022 |
Umsatz: | HKD7.16B |
Bruttogewinn: | HKD2.33B (32.61 %) |
EPS: | HKD0.500 |
FY | 2021 |
Umsatz: | HKD6.37B |
Bruttogewinn: | HKD2.03B (31.94 %) |
EPS: | HKD0.180 |
Financial Reports:
No articles found.
Shenzhen Hepalink Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.112 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.180 | 2021-05-28 |
Last Dividend | HKD0.112 | 2023-05-24 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD0.333 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.36 | -- |
Div. Sustainability Score | 3.30 | |
Div.Growth Potential Score | 2.21 | |
Div. Directional Score | 2.75 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9928.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
2180.HK | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
1181.HK | Ex Dividend Junior | 2023-09-13 | Annually | 0 | 0.00% | |
0257.HK | Ex Dividend Junior | 2023-09-25 | Semi-Annually | 0 | 0.00% | |
3888.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
1755.HK | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
0798.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
2338.HK | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
1313.HK | Ex Dividend Junior | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
0373.HK | Ex Dividend Junior | 2023-05-04 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.144 | 1.500 | -2.88 | -4.32 | [0 - 0.5] |
returnOnAssetsTTM | -0.0408 | 1.200 | -1.360 | -1.631 | [0 - 0.3] |
returnOnEquityTTM | -0.0638 | 1.500 | -1.820 | -2.73 | [0.1 - 1] |
payoutRatioTTM | -0.544 | -1.000 | -5.44 | 5.44 | [0 - 1] |
currentRatioTTM | 2.13 | 0.800 | 4.37 | 3.49 | [1 - 3] |
quickRatioTTM | 0.756 | 0.800 | -0.256 | -0.205 | [0.8 - 2.5] |
cashRatioTTM | 0.371 | 1.500 | 9.05 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.290 | -1.500 | 5.17 | -7.76 | [0 - 0.6] |
interestCoverageTTM | -3.86 | 1.000 | -2.54 | -2.54 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.462 | 2.00 | 9.85 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.159 | 2.00 | 9.92 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.467 | -1.500 | 8.13 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.331 | 1.000 | 7.82 | 7.82 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.158 | 1.000 | -5.16 | -5.16 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.122 | 1.000 | -0.433 | -0.433 | [0.2 - 2] |
assetTurnoverTTM | 0.284 | 0.800 | -1.443 | -1.154 | [0.5 - 2] |
Total Score | 3.30 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -6.02 | 1.000 | -0.709 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0638 | 2.50 | -1.170 | -2.73 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.159 | 2.00 | 9.95 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.49 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.462 | 2.00 | 9.85 | 10.00 | [0 - 30] |
payoutRatioTTM | -0.544 | 1.500 | -5.44 | 5.44 | [0 - 1] |
pegRatioTTM | -0.0488 | 1.500 | -3.66 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.125 | 1.000 | 9.38 | 0 | [0.1 - 0.5] |
Total Score | 2.21 |
Shenzhen Hepalink
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.